Oryzon Secures New Vafidemstat Patents in Key Markets

  • Oryzon received new patent grants for vafidemstat in South Korea, Mexico, New Zealand, and the Philippines.
  • Patents cover non-aggressive symptoms of borderline personality disorder (BPD) and autism spectrum disorder (ASD).
  • U.S. patent for vafidemstat expected to remain in force until at least 2043.
  • Vafidemstat is in advanced clinical development for psychiatric and neurodevelopmental disorders.
  • Oryzon is expanding vafidemstat's development into genetically defined patient populations.

Oryzon's latest patent grants strengthen its global intellectual property protection for vafidemstat, a key asset in its pipeline for psychiatric and neurodevelopmental disorders. The move aligns with broader industry trends toward precision medicine and epigenetic modulation, positioning Oryzon to capitalize on growing demand for targeted therapies in CNS disorders. The extended patent lifespans, particularly in the U.S., provide a long-term competitive advantage in a crowded biopharmaceutical landscape.

Patent Strategy
How Oryzon's expanded patent portfolio will impact its competitive positioning in the epigenetics space.
Clinical Milestones
The pace at which vafidemstat advances through Phase III trials for BPD and other indications.
Market Expansion
Whether Oryzon can leverage these patents to secure partnerships or licensing deals in new regions.